首页> 外文期刊>The journal of immunology >Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
【24h】

Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype

机译:IL-21的肿瘤内递送通过将肿瘤相关的巨噬细胞从M2型转移到M1型来克服抗Her2 / Neu耐药性。

获取原文
           

摘要

Tumor resistance is a major hurdle to anti-Her2eu Ab–based cancer therapy. Current strategies to overcome tumor resistance focus on tumor cell–intrinsic resistance. However, the extrinsic mechanisms, especially the tumor microenvironment, also play important roles in modulating the therapeutic response and resistance of the Ab. In this study, we demonstrate that tumor progression is highly associated with TAMs with immune-suppressive M2 phenotypes, and deletion of TAMs markedly enhanced the therapeutic effects of anti-Her2eu Ab in a HER2eu-dependent breast cancer cell TUBO model. Tumor local delivery of IL-21 can skew TAM polarization away from the M2 phenotype to a tumor-inhibiting M1 phenotype, which rapidly stimulates T cell responses against tumor and dramatically promotes the therapeutic effect of anti-Her2 Ab. Skewing of TAM polarization by IL-21 relies substantially on direct action of IL-21 on TAMs rather than stimulation of T and NK cells. Thus, our findings identify the abundant TAMs as a major extrinsic barrier for anti-Her2eu Ab therapy and present a novel approach to combat this extrinsic resistance by tumor local delivery of IL-21 to skew TAM polarization. This study offers a therapeutic strategy to modulate the tumor microenvironment to overcome tumor-extrinsic resistance.
机译:抗药性是抗基于Her2 / neu Ab的癌症治疗的主要障碍。当前克服肿瘤耐药性的策略集中在肿瘤细胞内在耐药性上。然而,外部机制,尤其是肿瘤微环境,在调节抗体的治疗反应和耐药性方面也起着重要作用。在这项研究中,我们证明肿瘤的进展与具有免疫抑制性M2表型的TAM高度相关,并且在HER2 / neu依赖性乳腺癌细胞TUBO模型中,TAM的缺失显着增强了抗Her2 / neu Ab的治疗作用。 IL-21的肿瘤局部递送可以使TAM极化从M2表型偏向抑制肿瘤的M1表型,从而迅速刺激T细胞对肿瘤的反应并显着促进抗Her2 Ab的治疗作用。 IL-21对TAM极化的偏斜基本上取决于IL-21对TAM的直接作用,而不是刺激T和NK细胞。因此,我们的发现将丰富的TAM鉴定为抗Her2 / neu Ab治疗的主要外在屏障,并提出了通过将IL-21局部转移至偏TAM极化来对抗这种外在抗性的新方法。这项研究提供了一种治疗策略,可调节肿瘤的微环境以克服肿瘤的外源性耐药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号